[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,208,858
  • Shares Outstanding, K 96,666
  • Annual Sales, $ 7,500 K
  • Annual Income, $ -345,910 K
  • EBIT $ -442 M
  • EBITDA $ -439 M
  • 60-Month Beta 0.62
  • Price/Sales 841.12
  • Price/Cash Flow N/A
  • Price/Book 5.08

Options Overview Details

View History
  • Implied Volatility 49.72% (-2.04%)
  • Historical Volatility 42.31%
  • IV Percentile 30%
  • IV Rank 6.87%
  • IV High 176.33% on 02/20/26
  • IV Low 40.38% on 05/19/26
  • Expected Move (DTE 7) 3.15 (5.04%)
  • Put/Call Vol Ratio 10.40
  • Today's Volume 114
  • Volume Avg (30-Day) 728
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 25,967
  • Open Int (30-Day) 23,444
  • Expected Range 59.40 to 65.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.17
  • Number of Estimates 8
  • High Estimate $-0.98
  • Low Estimate $-1.36
  • Prior Year $-1.15
  • Growth Rate Est. (year over year) -1.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.16 +1.28%
on 08/03/26
69.58 -10.98%
on 07/17/26
-5.36 (-7.96%)
since 07/14/26
3-Month
50.91 +21.67%
on 06/08/26
72.66 -14.75%
on 07/09/26
+5.94 (+10.61%)
since 05/14/26
52-Week
35.60 +73.99%
on 09/15/25
72.66 -14.75%
on 07/09/26
+23.98 (+63.17%)
since 08/14/25

Most Recent Stories

More News
Xenon Pharmaceuticals: Q2 Earnings Snapshot

Xenon Pharmaceuticals: Q2 Earnings Snapshot

XENE : 62.14 (-3.25%)
Xenon Reports Q2 2026 Financial Results and Provides Business Update

NDA submission for azetukalner on track for Q3 2026  following pre-NDA meeting with FDA Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll Three Phase 3 studies of azetukalner...

XENE : 62.14 (-3.25%)
Xenon Pharmaceuticals: The Gap Between Clinical Progress and Revenue Begins Thursday

Barchart Research What to Expect from XENE Earnings XENE Generated August 5, 2026 Current Price $64.30 EPS Estimate $$-1.16 Consensus Rating Strong Buy Average Move 5.28% Xenon Pharmaceuticals: The Gap...

XENE : 62.14 (-3.25%)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development,...

XENE : 62.14 (-3.25%)
Xenon to Report Q2 2026 Financial Results on August 6, 2026

VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development,...

XENE : 62.14 (-3.25%)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 62.14 (-3.25%)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 62.14 (-3.25%)
Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure...

XENE : 62.14 (-3.25%)
Xenon Pharmaceuticals: Q1 Earnings Snapshot

Xenon Pharmaceuticals: Q1 Earnings Snapshot

XENE : 62.14 (-3.25%)
Xenon Reports Q1 2026 Financial Results and Provides Business Update

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026 Five additional Phase 3 studies of azetukalner continue to enroll in...

XENE : 62.14 (-3.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan...

See More

Key Turning Points

3rd Resistance Point 67.35
2nd Resistance Point 66.52
1st Resistance Point 65.38
Last Price 62.14
1st Support Level 63.41
2nd Support Level 62.58
3rd Support Level 61.44

See More

52-Week High 72.66
Last Price 62.14
Fibonacci 61.8% 58.50
Fibonacci 50% 54.13
Fibonacci 38.2% 49.76
52-Week Low 35.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.